×

How will Pharmacyclics complement AbbVie?

5:23 PM ET Thu, 5 March 2015

Sachin Shah, merger arbitrage strategist at Albert Fried and Company, discusses why AbbVie's decision to buy Pharmacyclics for about $21 billion is a "longer-dated" move.